Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells

Cancer Gene Therapy

Volumn 12, Issue 5, 2005, Pages 464-474

  Finger, Carsten ^a   Sun, Yuansheng ^a   Sanz, Laura ^b   Alvarez Vallina, Luis ^b   Buchholz, Christian J ^a   Cichutek, Klaus ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cytokine; Gene delivery; Laminin; ML V; Retrovirus; scFv

Indexed keywords

ENVELOPE PROTEIN; FURIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; LAMININ; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENVELOPE GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; FLOW CYTOMETRY; GENE INSERTION; GENE THERAPY; GENETIC STABILITY; HUMAN; HUMAN CELL; LYMPHOID CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; NEOPLASMS; PLASMIDS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; VIRUS REPLICATION;

MURINAE; MURINE LEUKEMIA VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 18244396569     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700805     Document Type: Article

References (44)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997; 89:21-39.
2. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Therapy. 2000;7:2-8.
3. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354-1361.
4. Kruse CA, Roper MD, Kleinschmidt-DeMasters BK, et al. Purified herpes simplex thymidine kinase retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther. 1997;4:118-128.
5. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994;30A: 1165-1171.
6. Yoon TK, Shichinohe T, Laquerre S, Kasahara N. Selectively replicating adenoviruses for oncolytic therapy. Curr Cancer Drug Targets. 2001;1:85-107.
7. Mullen JT, Tanabe KK. Viral oncolysis. The Oncologist. 2002;7:106-119.
8. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. 2003;10: 292-303.
9. Vile RG, Sunassee K, Diaz RM. Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today. 1998;4:84-92.
10. Peng KW, Russell SJ. Viral vector targeting. Curr Opin Biotechnol. 1999;10:454-457.
11. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther. 2000;2: 433-440.
12. Bansal K, Engelhard HH. Gene therapy for brain tumors. Curr Oncol Rep. 2000;2:463-472.
13. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
14. Regulier E, Paul S, Marigliano M, et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. 2001;8:45-54.
15. Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther. 2001;3: 186-196.
16. Li H, Lindenmeyer F, Grenet C, et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther. 2001;12:515-526.
17. Sanz L, Kristensen P, Blanco B, et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Therapy. 2002;9:1049-1053.
18. Dillon PJ, Lenz J, Rosen CA. Construction of a replication-competent murine retrovirus vector expressing the human immunodeficiency virus type 1 tat transactivator protein. J Virol. 1991;65:4490-4493.
19. Reik W, Weiher H, Jaenisch R. Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences. Proc Natl Acad Sci USA. 1985;82:1141-1145.
20. Stuhlmann H, Jaenisch R, Mulligan RC. Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol Cell Biol. 1989;9:100-108.
21. Buchholz CJ, Peng KW, Morling FJ, et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol. 1998;16:951-954.
22. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J. 1997;327:625-635.
23. Sanz L, Kristensen P, Russell SJ, Ramirez Garcia JR, Alvarez-Vallina L. Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother. 2001;50:557-565.
24. Engelstadter M, Bobkova M, Baier M, et al. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum Gene Ther. 2000;11:293-303.
25. Schneider RM, Medvedovska Y, Hartl I, et al. Directed evolution of retroviruses activatable by tumor-associated matrix metalloproteases. Gene Therapy. 2003;10:1370-1380.
26. Sorokin L, Girg W, Gopfert T, Hallmann R, Deutzmann R. Expression of novel 400-kDa laminin chains by mouse and bovine endothelial cells. Eur J Biochem. 1994;223: 603-610.
27. Ekblom M, Falk M, Salmivirta K, Durbeej M, Ekblom P. Laminin isoforms and epithelial development. Ann N Y Acad Sci. 1998;857:194-211.
28. Miosge N. The ultrastructural composition of basement membranes in vivo. Histol Histopathol. 2001;16:1239-1248.
29. Jespersen T, Duch M, Carrasco ML, Warming S, Pedersen FS. Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors. Gene. 1999;239:227-235.
30. Miller AD. Development and applications of retroviral vectors. In: Coffin JM, Hughes HH, Varmus HE, eds. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997: 437-474.
31. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther. 2001;12:921-932.
32. Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J Virol. 2001;75:6989-6998.
33. Wang WJ, Tai C-K, Kasahara N, Chen TC. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther. 2003;14:117-127.
34. Liu YC, Kawagishi M, Mikayama T, et al. Processing of a fusion protein by endoprotease in COS-1 cells for secretion of mature peptide by using a chimeric expression vector. Proc Natl Acad Sci USA. 1993;90:8957-8961.
35. Groskreutz DJ, Sliwkowski MX, Gorman CM. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem. 1994;269:6241-6245.
36. Gaken J, Jiang J, Daniel K, et al. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Therapy. 2000;7:1979-1985.
37. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol. 2003;281: 137-178.
38. Murray L, Luens K, Tushinski R, et al. Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. Hum Gene Ther. 1999;10: 1743-1752.
39. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med. 1992;176: 1125-1135.
40. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science. 2002;298:34-35.
41. Nilson BH, Morling FJ, Cosset FL, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Therapy. 1996;3:280-286.
42. Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol. 2002;76:12783-12791.
43. Diaz RM, Eisen T, Hart IR, et al. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol. 1998;72: 789-795.
44. Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol. 1999;73:9702-9709.